PPBT (Purple Biotech) Total Equity: $9.66 Mil (As of Mar. 2026)


PPBT Purple Biotech Ltd PPBT
25 GF Score
Price $1.74
! 2 Warning Signs
View Full Analysis

What is Purple Biotech Total Equity?

Purple Biotech PPBT +3.57% 25 Total Equity is $9.66 Mil as of Mar. 2026. GuruFocus rates PPBT with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

Purple Biotech's total equity for the quarter that ended in Mar. 2026 was $9.66 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Purple Biotech Total Equity Historical Data

* Premium members only.

The historical data trend for Purple Biotech's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Purple Biotech Total Equity Chart

Purple Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.11 47.10 34.30 32.91 9.66

Purple Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.70 32.05 32.82 9.66 9.66
PPBT
25GF Score
Purple Biotech Ltd PPBT
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Purple Biotech Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Purple Biotech's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=17.572-7.913
=9.66

Purple Biotech's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=14.417-4.753
=9.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $9.66 Mil mean?
Purple Biotech (PPBT) has a Total Equity of $9.66 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Purple Biotech and its competitors.
Is Purple Biotech's Total Equity too high?
Purple Biotech's current Total Equity is $9.66 Mil. Overall, Purple Biotech has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Purple Biotech's Total Equity compare to VRTX and REGN?
Purple Biotech's Total Equity of $9.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Purple Biotech and its competitors. Purple Biotech's current Total Equity is $9.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Purple Biotech stock overvalued right now?
Purple Biotech (PPBT) has a current Total Equity of $9.66 Mil. The current Total Equity is $9.66 Mil. Purple Biotech's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Purple Biotech (PPBT), the current Total Equity is $9.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Purple Biotech Business Description

Other Exchanges PPBT:Israel
Address 4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
25GF Score

Get the complete analysis for PPBT

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.74
Price